Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens

AIDS Research and Human Retroviruses

Volumn 17, Issue 12, 2001, Pages 1107-1115

  Ross, Lisa ^a   Scarsella, Anthony ^b   Raffanti, Stephen ^c   Henry, Keith ^d   Becker, Stephen ^e   Fisher, Robin ^a   Liao, Qiming ^a   Hirani, Ashwin ^a   Graham, Neil ^a   Clair, Marty St ^a   Hernandez, Jaime ^a  

^a GLAXOSMITHKLINE   (United States)

^b Pacific Oaks Medical Center   (United States)

^c Comprehensive Care Center ^*  (United States)

^d REGIONS HOSPITAL   (United States)

^e Pacific Horizon Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATION; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; VIREMIA; VIRUS ISOLATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; THYMIDINE; VIREMIA; ZIDOVUDINE;

EID: 0034828314     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201316912718     Document Type: Article

References (30)

1. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
2. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
3. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy
4. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
5. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
6. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy
7. Mutations in thepol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
8. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy
9. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
10. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
11. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine
12. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction
13. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
14. Significance of amino acid variation at human immunodeficiency virus type I reverse transcriptase residue 210 for zidovudine susceptibility
15. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
16. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors
18. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
19. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′3′-dideoxynucleoside 5′-triphosphates
20. Altered drug sensitivity, fitness and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi dideoxynucleoside resistance
21. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type I isolates from patients treated with antiretroviral drugs
22. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
23. Stavudine resistance: An update on susceptibility following prolonged therapy
24. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
25. Occurrence of thymidine-associated mutations in naive patients treated more than 6 months by stavudine/lamivudine bi-therapy combination and tritherapies including stavudine/didanosine or stavudine/lamivudine
26. Zidovudine genotypic and phenotypic resistance arising in patients never exposed to zidovudine
27. Prevalence of zidovudine and lamivudine-resistance-related mutation in the absence of active zi-dovudine or lamivudine use in a large, multi-centered, comparative trial of genotyping and standard of care - The Havanna trial
28. Selection of zidovudine resistance mutations by zidovudine or stavudine-based regimens and relationship to subsequent virologic response in ACTG 370
29. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
30. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy